Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Luma Group is a New York-based venture capital firm founded in 2023, focusing on early and mid-stage biotechnology companies. The firm was established by Josh Fink and Themasap Khan, PhD, who bring extensive experience in private equity and biotech investing. Luma Group integrates AI-driven analysis with scientific rigor to support innovative healthcare solutions, particularly in precision medicine and breakthrough biology.
Currently, Luma Group operates with a team of experts, including professionals with advanced degrees in relevant scientific fields. The firm emphasizes a strong commitment to funding companies that are grounded in solid scientific principles and data. Although specific metrics such as assets under management (AUM) and fund sizes are not disclosed, Luma Group has already made significant strides in the industry, including co-leading a Series C investment in ArsenalBio.
Headquartered in New York, Luma Group is positioned to leverage its location in a major biotech hub. The firm aims to scale patient impact through its investments, focusing on therapies, diagnostics, and medical devices that can significantly improve healthcare outcomes.
Luma Group invests in biotechnology companies at various stages, including pre-seed, seed, seed-plus, Series A, and Series B. The firm emphasizes a data-driven approach, seeking companies that demonstrate strong scientific principles. Their investment strategy is centered on next-generation therapeutics, AI/ML technologies for early disease detection, and advanced medical devices.
The firm provides more than just financial capital; it offers strategic, operational, and scientific support to its portfolio companies. This includes leveraging their proprietary AI intelligence platform, LABI, which aggregates biological data, clinical trial data, and market dynamics to deliver validated insights. Luma Group's focus on precision medicine and breakthrough biology aligns with their goal of advancing human health outcomes through technology-driven investments.
Luma Group has notably co-led a Series C investment in ArsenalBio, a company focused on developing innovative therapies for cancer treatment. This investment was made in partnership with ARCH Ventures and Regeneron Ventures, showcasing Luma Group's commitment to supporting science-driven teams. While specific names or descriptions of other portfolio companies are not publicly disclosed, the firm is known for its focus on biotechnology sectors, particularly in precision medicine and diagnostics.
As Luma Group continues to build its portfolio, it is expected to attract additional companies that align with its investment thesis. The firm’s emphasis on strong scientific principles and data-driven approaches positions it well to identify and support promising biotech innovations.
Josh Fink — Founder & Managing Member. He has over 20 years of experience in private and public investments and previously co-founded Luma Bio-IT SPV. He is also a member of the World Economic Forum.
Themasap Khan, PhD — Co-Founder & Partner. Dr. Khan has over 10 years of experience in biotech investing and operational roles, contributing to Luma Group's strategic direction.
Jamie Kasuboski, PhD — Partner & Head of Research. Dr. Kasuboski brings over 10 years of experience in biotech investing and operational expertise, enhancing the firm’s research capabilities.
Bill Ryan — Chief Financial Officer. He oversees the financial operations of Luma Group, ensuring sound financial management.
John Gomez — Senior Associate. He supports investment analysis and portfolio management.
Miguel “Miggy” Chuapoco, PhD — Associate. Dr. Chuapoco contributes to investment research and due diligence.
Richie Santry — Chief of Staff. He manages operations and strategic initiatives within the firm.
Tamara Young — Executive Assistant. She provides administrative support to the team.
Neel Madhukar, PhD — Chief Technology Officer of LABI. He leads the development of the AI intelligence platform.
James
To pitch Luma Group, founders should use the contact form available on their website at lumagroup.com. It is essential to include a comprehensive pitch deck that outlines the scientific foundation of the technology, the team’s expertise, and the market opportunity. Luma Group appreciates detailed information that demonstrates a strong understanding of the biotech landscape.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
In September 2024, Luma Group co-led a Series C investment in ArsenalBio, partnering with ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, T. Rowe Price Associates, and Rock Springs Capital.
What are Luma Group's investment criteria?
Luma Group focuses on biotechnology companies that are grounded in strong scientific principles and data. They invest in early and mid-stage companies, including pre-seed, seed, seed-plus, Series A, and Series B stages.
How can I apply or pitch to Luma Group?
Founders can pitch to Luma Group through their website at lumagroup.com. It is advisable to include detailed information about the scientific basis of the technology, market potential, and the team’s expertise in the pitch deck.
What makes Luma Group different from other venture capital firms?
Luma Group integrates AI-driven analysis with scientific rigor, providing not only financial support but also strategic, operational, and scientific assistance to its portfolio companies. Their proprietary platform, LABI, offers real-time insights that enhance decision-making.
What is Luma Group's geographic focus?
The firm primarily invests in biotechnology companies located in the United States, emphasizing the importance of strong scientific foundations and data-driven approaches.
What is the typical check size for investments?
Luma Group typically invests between $5 million and $20 million in initial funding rounds, leading or co-leading financings at the Series A and B levels.
What kind of post-investment involvement does Luma Group have?
Luma Group provides ongoing strategic, operational, and scientific support to its portfolio companies, leveraging its expertise and resources to help them scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.